Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR5 | P32302 | 4/20 | 0.56 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.55 |
| ▸ | BAD | Q92934 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 6/20 | 0.49 |
| ▸ | RXRB | P28702 | 5/20 | 0.49 |
| ▸ | RXRG | P48443 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29493191 | 1.00 | CXCR5 (0.56) | CXCR5BCL2L1BADGFERMEN1 | |
| SCHEMBL5755502 | 0.98 | CXCR5 (0.55) | CXCR5BCL2L1BADGFERMEN1 | |
| Hydrochloric Acid SCHEMBL2398251 | 0.98 | CXCR5 (0.55) | CXCR5BCL2L1BADGFERMEN1 | |
| SCHEMBL3613341 | 0.96 | CXCR5 (0.53) | CXCR5BCL2L1BADGFERMEN1 | |
| Adamantane SCHEMBL28516622 | 0.89 | CXCR5 (0.49) | CXCR5BCL2L1BADGFERMEN1 | |
| SCHEMBL11814300 | 0.88 | BCL2L1 (0.55) | CXCR5BCL2L1BADGFERMEN1 | |
| SCHEMBL11001708 | 0.87 | HSP90AA1 (0.51) | CXCR5BCL2L1BADGFERMEN1 | |
| SCHEMBL15330692 | 0.87 | ALDH1A1 (0.50) | CXCR5GFERALDH1A1ALOX15TRPA1 | |
| SCHEMBL29950657 | 0.87 | ALDH1A1 (0.50) | CXCR5GFERALDH1A1ALOX15TRPA1 | |
| SCHEMBL8204167 | 0.86 | CXCR5 (0.52) | CXCR5BCL2L1BADGFERMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111440137-B | 3, 4-benzocoumarin derivative and preparation method and application thereof | 华东理工大学 | 2022-08-16 | — | — | CN | claimed |
| CN-114428064-A | Method for detecting content of nitrate ions in copper etching solution | 江苏和达电子科技有限公司 | 2022-05-03 | — | — | CN | claimed |
| CN-113248407-A | Multifunctional aromatic amine compound and preparation method and application thereof | 中南民族大学 | 2021-08-13 | — | — | CN | claimed |
| CN-111440137-A | 3, 4-benzocoumarin derivative and preparation method and application thereof | 华东理工大学 | 2020-07-24 | — | — | CN | claimed |
| CN-110642741-A | Functionalized benzamide derivatives as antiviral agents against HBV infection | 巴鲁克斯布隆伯格研究所 | 2020-01-03 | — | — | CN | claimed |
| CN-104918612-B | Functionalized benzamide derivatives as antiviral agents against HBV infection | 巴鲁克斯布隆伯格研究所 | 2019-10-25 | — | — | CN | claimed |
| US-20150307443-A1 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | BARUCH S BLUMBERG INST (US) | 2015-10-29 | — | — | US | claimed |
| EP-2928459-A2 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | Baruch S. Blumberg Institute (US) | 2015-10-14 | — | — | EP | claimed |
| CN-104918612-A | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | INST HEPATITIS & VIRUS RES | 2015-09-16 | — | — | CN | claimed |
| WO-2014089296-A2 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH (US) | 2014-06-12 | — | — | WO | claimed |
| WO-2011013095-A1 | PROCESSES FOR THE PREPARATION OF PALONOSETRON | RANBAXY LABORATORIES LIMITED (IN) | 2011-02-03 | — | — | WO | claimed |
| EP-0511087-B1 | Sweetening agents derived from l-glutamic acid; process for their preparation | NOFRE CLAUDE (FR) | 1995-06-28 | — | — | EP | claimed |
| US-20260125348-A1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | OREGON STATE UNIVERSITY (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4710922-A2 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | Oregon State University (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4003337-B1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | UNIV OREGON STATE (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-5272272-A | Sweetening agents derived from L-glutamic acid | NOFRE CLAUDE (FR) | 1993-12-21 | — | — | US | disclosed |
| US-5202333-A | Tricyclic 5-HT3 receptor antagonists | SYNTEX (U.S.A.) INC. (US) | 1993-04-13 | — | — | US | disclosed |
| EP-0430190-A2 | New tricyclic compounds | SYNTEX (U.S.A.) INC. (US) | 1991-06-05 | — | — | EP | disclosed |
| US-4011326-A | 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents | MERCK & CO., INC. (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307443-A1 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | HAVCR2, PHB2, PHB1 | CXCR5 736/4885BCL2L1 470/4885BAD 33/4885 |
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | CXCR5 1654/4885BCL2L1 344/4885BAD 2338/4885 |
| US-20260125348-A1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | AHR, ARNT, NR1H2 | CXCR5 369/4885BCL2L1 945/4885BAD 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.